142 related articles for article (PubMed ID: 25529566)
21. Lipid core peptide technology and group A streptococcal vaccine delivery.
Olive C; Batzloff MR; Toth I
Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
[TBL] [Abstract][Full Text] [Related]
22. Active immunisation of mice with GnRH lipopeptide vaccine candidates: Importance of T helper or multi-dimer GnRH epitope.
Goodwin D; Simerska P; Chang CH; Mansfeld FM; Varamini P; D'Occhio MJ; Toth I
Bioorg Med Chem; 2014 Sep; 22(17):4848-54. PubMed ID: 25059504
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus.
Simerska P; Abdel-Aal AB; Fujita Y; Batzloff MR; Good MF; Toth I
Biopolymers; 2008; 90(5):611-6. PubMed ID: 18381625
[TBL] [Abstract][Full Text] [Related]
24. A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes.
Zhao L; Yang J; Nahar UJ; Khalil ZG; Capon RJ; Hussein WM; Skwarczynski M; Toth I
Bioorg Med Chem; 2020 Dec; 28(24):115823. PubMed ID: 33120079
[TBL] [Abstract][Full Text] [Related]
25. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.
Zaman M; Skwarczynski M; Malcolm JM; Urbani CN; Jia Z; Batzloff MR; Good MF; Monteiro MJ; Toth I
Nanomedicine; 2011 Apr; 7(2):168-73. PubMed ID: 21034860
[TBL] [Abstract][Full Text] [Related]
26. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
[TBL] [Abstract][Full Text] [Related]
27. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
[TBL] [Abstract][Full Text] [Related]
28. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.
Dale JB; Penfound T; Chiang EY; Long V; Shulman ST; Beall B
Clin Diagn Lab Immunol; 2005 Jul; 12(7):833-6. PubMed ID: 16002631
[TBL] [Abstract][Full Text] [Related]
29. Lipopeptide Nanoparticles: Development of Vaccines against Hookworm Parasite.
Fuaad AA; Pearson MS; Pickering DA; Becker L; Zhao G; Loukas AC; Skwarczynski M; Toth I
ChemMedChem; 2015 Oct; 10(10):1647-54. PubMed ID: 26269385
[TBL] [Abstract][Full Text] [Related]
30. A vaccine against Streptococcus pyogenes: the potential to prevent rheumatic fever and rheumatic heart disease.
Guilherme L; Ferreira FM; Köhler KF; Postol E; Kalil J
Am J Cardiovasc Drugs; 2013 Feb; 13(1):1-4. PubMed ID: 23355360
[TBL] [Abstract][Full Text] [Related]
31. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate.
Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L
Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
[TBL] [Abstract][Full Text] [Related]
33. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
[TBL] [Abstract][Full Text] [Related]
34. Enhanced immunogenicity of an anti-caries vaccine encoding a cell-surface protein antigen of Streptococcus mutans by intranasal DNA prime-protein boost immunization.
Li Y; Jin J; Yang Y; Bian Z; Chen Z; Fan M
J Gene Med; 2009 Nov; 11(11):1039-47. PubMed ID: 19718694
[TBL] [Abstract][Full Text] [Related]
35. Production of mouse monoclonal antibody against Streptococcus dysgalactiae GapC protein and mapping its conserved B-cell epitope.
Zhang L; Zhang H; Fan Z; Zhou X; Yu L; Sun H; Wu Z; Yu Y; Song B; Ma J; Tong C; Zhu Z; Cui Y
Res Vet Sci; 2015 Feb; 98():39-41. PubMed ID: 25468796
[TBL] [Abstract][Full Text] [Related]
36. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2.
Zaman M; Abdel-Aal AM; Phillipps KSM; Fujita Y; Good MF; Toth I
Vaccine; 2010 Mar; 28(10):2243-2248. PubMed ID: 20045502
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and characterisation of self-assembled and self-adjuvanting asymmetric multi-epitope lipopeptides of ovalbumin.
Eskandari S; Stephenson RJ; Fuaad AA; Apte SH; Doolan DL; Toth I
Chemistry; 2015 Jan; 21(3):1251-61. PubMed ID: 25399845
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope.
Simerska P; Lu H; Toth I
Bioorg Med Chem Lett; 2009 Feb; 19(3):821-4. PubMed ID: 19097790
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III.
Lancaster L; Saydam M; Markey K; Ho MM; Mawas F
Vaccine; 2011 Apr; 29(17):3213-21. PubMed ID: 21356338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
